In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Cytori Therapeutics Inc (CYTX), with a price target of $3. The company’s shares closed yesterday at $0.34, close to its 52-week low of $0.31.
According to TipRanks.com, Kolbert has 0 stars on 0-5 star ranking scale with an average return of -8.3% and a 33.0% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Coherus Biosciences, and Can-Fite BioPharma.
Currently, the analyst consensus on Cytori Therapeutics Inc is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.40 and a one-year low of $0.31. Currently, Cytori Therapeutics Inc has an average volume of 872.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytori Therapeutics, Inc. is a late stage cell therapy company which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.
